[Education] Lung Cancer: Top 10 Clinical Pearls

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Daniel Melzer highlights the top ten clinical pearls regarding various forms and stages of lung cancer and the treatment options for these different disease diagnoses. He also shares chemotherapy treatments and survival rates and other considerations that can help determine future therapy options in various diagnosis situations.

 

In this episode you will learn:

 

Lung Cancer Considerations and Treatments

• Stage four non-small cell lung cancer targeted therapy guidelines
• Diagnoses in which treatment must be an immunotherapy plus chemotherapy combination
• Metastatic disease considerations for first- and second-line setting situations
• The importance of histology when determining if a patient needs targeted therapy
• Chemotherapy treatment options and survival rates for stage one, two, and three cancer patients
• How first-line treatment for small cell lung cancer depends on staging
• Timing of relapse considerations to help determine future therapy options

 

Mentioned in This Episode:

HOPA

 

Tweetables:

 

“There is a higher overall rate of survival in patients that receive pembrolizumab in the first-line setting.” — Daniel Melzer

 

“In stage two and stage three patients, there is a survival benefit in receiving chemotherapy versus observation.” — Daniel Melzer

 

“First-line treatment for small cell lung cancer depends on staging.” — Daniel Melzer